Design Therapeutics Statistics
Total Valuation
DSGN has a market cap or net worth of $308.66 million. The enterprise value is $94.33 million.
Important Dates
The last earnings date was Thursday, August 7, 2025, before market open.
| Earnings Date | Aug 7, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
DSGN has 56.95 million shares outstanding. The number of shares has increased by 0.80% in one year.
| Current Share Class | 56.95M |
| Shares Outstanding | 56.95M |
| Shares Change (YoY) | +0.80% |
| Shares Change (QoQ) | +0.18% |
| Owned by Insiders (%) | 15.49% |
| Owned by Institutions (%) | 41.66% |
| Float | 25.72M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 1.45 |
| P/TBV Ratio | 1.45 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 25.13, with a Debt / Equity ratio of 0.01.
| Current Ratio | 25.13 |
| Quick Ratio | 24.88 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -26.77% and return on invested capital (ROIC) is -19.56%.
| Return on Equity (ROE) | -26.77% |
| Return on Assets (ROA) | -19.02% |
| Return on Invested Capital (ROIC) | -19.56% |
| Return on Capital Employed (ROCE) | -34.99% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.18M |
| Employee Count | 54 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +28.24% in the last 52 weeks. The beta is 1.58, so DSGN's price volatility has been higher than the market average.
| Beta (5Y) | 1.58 |
| 52-Week Price Change | +28.24% |
| 50-Day Moving Average | 4.00 |
| 200-Day Moving Average | 4.63 |
| Relative Strength Index (RSI) | 73.08 |
| Average Volume (20 Days) | 116,712 |
Short Selling Information
The latest short interest is 3.49 million, so 6.14% of the outstanding shares have been sold short.
| Short Interest | 3.49M |
| Short Previous Month | 3.53M |
| Short % of Shares Out | 6.14% |
| Short % of Float | 13.59% |
| Short Ratio (days to cover) | 36.14 |
Income Statement
| Revenue | n/a |
| Gross Profit | -44.53M |
| Operating Income | -74.93M |
| Pretax Income | -50.53M |
| Net Income | -63.49M |
| EBITDA | -74.31M |
| EBIT | -74.93M |
| Earnings Per Share (EPS) | -$1.12 |
Full Income StatementBalance Sheet
The company has $216.28 million in cash and $1.95 million in debt, giving a net cash position of $214.33 million or $3.76 per share.
| Cash & Cash Equivalents | 216.28M |
| Total Debt | 1.95M |
| Net Cash | 214.33M |
| Net Cash Per Share | $3.76 |
| Equity (Book Value) | 213.04M |
| Book Value Per Share | 3.74 |
| Working Capital | 211.05M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$50.64 million and capital expenditures -$143,000, giving a free cash flow of -$50.78 million.
| Operating Cash Flow | -50.64M |
| Capital Expenditures | -143,000 |
| Free Cash Flow | -50.78M |
| FCF Per Share | -$0.89 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |